Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New purines with antiplatelet activity.

Katrin Märschenz1, Klaus Rehse

  • 1Institut für Pharmazie, Freie Universität Berlin, Berlin, Germany.

Archiv Der Pharmazie
|February 24, 2006
PubMed
Summary

New purine derivatives were synthesized and tested for their ability to inhibit blood platelet aggregation. Compound 6b demonstrated potent anti-platelet activity, particularly against adenosine diphosphate (ADP)-induced aggregation, with potential therapeutic applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arylazoamidoximes and related compounds as NO-modulators.

Archiv der Pharmazie·2009
Same author

New 1H-pyrazole-4-carboxamides with antiplatelet activity.

Archiv der Pharmazie·2008
Same author

New 2-amino-thiazole-4-acetamides with antiplatelet activity.

Archiv der Pharmazie·2008
Same author

Synthesis and antiplatelet activity of new imidazole-4-carboxylic acid derivatives.

Archiv der Pharmazie·2005
Same author

New pyrimido[5,4-c]cinnolines with antiplatelet activities.

Archiv der Pharmazie·2005
Same author

New oxadiazole derivatives showing partly antiplatelet, antithrombotic and serotonin antagonistic properties.

Archiv der Pharmazie·2005

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Biochemistry

Background:

  • Blood platelet aggregation plays a critical role in thrombosis and hemostasis.
  • Developing novel inhibitors of platelet aggregation is crucial for managing cardiovascular diseases.

Purpose of the Study:

  • To synthesize and characterize novel purine derivatives.
  • To evaluate the anti-platelet aggregation activity of these compounds.
  • To investigate the mechanism of action of potent inhibitors.

Main Methods:

  • Synthesis of purine-2,6-diamines, N-(purin-2-yl)benzenecarboxamides, and N-(purin-2-yl)-2-furanecarboxamide derivatives.
  • Assessment of inhibition of collagen-induced platelet aggregation using the Born test.
  • Evaluation of anti-aggregating activity against adenosine diphosphate (ADP), platelet-activating factor (PAF), and adrenaline using specific inducers.

Main Results:

  • Six compounds (6a, b, h, m, o, p) inhibited collagen-induced platelet aggregation with IC50 values between 3-10 µmol/L.
  • Several compounds exhibited potent activity in the nanomolar to subnanomolar range against specific inducers.
  • Compound 6b showed significant inhibition of ADP-induced aggregation (IC50 = 0.45 nM).
  • Compound 7b displayed strong antagonism against adrenaline (IC50 = 1.8 nM) and PAF (IC50 = 1 nM).

Conclusions:

  • The synthesized purine derivatives possess significant anti-platelet aggregation properties.
  • Compounds 6b and 7b are highly potent inhibitors and warrant further investigation for antithrombotic potential.
  • The study provides novel chemical entities for the development of anti-platelet therapies.

Related Experiment Videos